Cargando…
Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics
Congenital heart disease (CHD) is the most common birth defect. The prenatal diagnosis of fetal CHD is completely dependent on ultrasound testing, but only ~40% of CHD can be detected. The purpose of this study is to find good biomarkers in amniotic fluid (AF) to detect CHD in the second trimester,...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215886/ https://www.ncbi.nlm.nih.gov/pubmed/34164441 http://dx.doi.org/10.3389/fcvm.2021.671191 |
_version_ | 1783710325411938304 |
---|---|
author | Li, Yahong Sun, Yun Yang, Lan Huang, Mingtao Zhang, Xiaojuan Wang, Xin Guan, Xianwei Yang, Peiying Wang, Yan Meng, Lulu Zhou, Ran Zhou, Xiaoyan Luo, Chunyu Hu, Ping Jiang, Tao Xu, Zhengfeng |
author_facet | Li, Yahong Sun, Yun Yang, Lan Huang, Mingtao Zhang, Xiaojuan Wang, Xin Guan, Xianwei Yang, Peiying Wang, Yan Meng, Lulu Zhou, Ran Zhou, Xiaoyan Luo, Chunyu Hu, Ping Jiang, Tao Xu, Zhengfeng |
author_sort | Li, Yahong |
collection | PubMed |
description | Congenital heart disease (CHD) is the most common birth defect. The prenatal diagnosis of fetal CHD is completely dependent on ultrasound testing, but only ~40% of CHD can be detected. The purpose of this study is to find good biomarkers in amniotic fluid (AF) to detect CHD in the second trimester, so as to better manage this group of people and reduce the harm of CHD to the fetus. Metabolites analysis were performed in two separate sets. The discovery set consisted of 18 CHD fetal maternal AF samples and 35 control samples, and the validation set consisted of 53 CHD fetal maternal AF samples and 114 control samples. Untargeted metabolite profiles were analyzed by gas chromatography/time-of-flight-mass spectrometry (GC-TOF/MS). Orthogonal partial least square discrimination analysis (OPLS-DA) demonstrated that CHD and control samples had significantly different metabolic profiles. Two metabolites, uric acid and proline, were significantly elevated in CHD and verified in two data sets. Uric acid was associated with CHD [odds ratio (OR): 7.69 (95% CI: 1.18–50.13) in the discovery set and 3.24 (95% CI:1.62–6.48) in the validation set]. Additionally, uric acid showed moderate predictive power; the area under curve (AUC) was 0.890 in the discovery set and 0.741 in the validation set. The sensitivity and specificity of uric acid to detect CHD was, respectively, 94.4 and 74.3% in the discovery set and 67.9 and 71.9% in the validation set. The identification of uric acid as a biomarker for CHD has the potential to stimulate research on the pathological mechanism of CHD and the development of a diagnostic test for clinical applications. |
format | Online Article Text |
id | pubmed-8215886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82158862021-06-22 Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics Li, Yahong Sun, Yun Yang, Lan Huang, Mingtao Zhang, Xiaojuan Wang, Xin Guan, Xianwei Yang, Peiying Wang, Yan Meng, Lulu Zhou, Ran Zhou, Xiaoyan Luo, Chunyu Hu, Ping Jiang, Tao Xu, Zhengfeng Front Cardiovasc Med Cardiovascular Medicine Congenital heart disease (CHD) is the most common birth defect. The prenatal diagnosis of fetal CHD is completely dependent on ultrasound testing, but only ~40% of CHD can be detected. The purpose of this study is to find good biomarkers in amniotic fluid (AF) to detect CHD in the second trimester, so as to better manage this group of people and reduce the harm of CHD to the fetus. Metabolites analysis were performed in two separate sets. The discovery set consisted of 18 CHD fetal maternal AF samples and 35 control samples, and the validation set consisted of 53 CHD fetal maternal AF samples and 114 control samples. Untargeted metabolite profiles were analyzed by gas chromatography/time-of-flight-mass spectrometry (GC-TOF/MS). Orthogonal partial least square discrimination analysis (OPLS-DA) demonstrated that CHD and control samples had significantly different metabolic profiles. Two metabolites, uric acid and proline, were significantly elevated in CHD and verified in two data sets. Uric acid was associated with CHD [odds ratio (OR): 7.69 (95% CI: 1.18–50.13) in the discovery set and 3.24 (95% CI:1.62–6.48) in the validation set]. Additionally, uric acid showed moderate predictive power; the area under curve (AUC) was 0.890 in the discovery set and 0.741 in the validation set. The sensitivity and specificity of uric acid to detect CHD was, respectively, 94.4 and 74.3% in the discovery set and 67.9 and 71.9% in the validation set. The identification of uric acid as a biomarker for CHD has the potential to stimulate research on the pathological mechanism of CHD and the development of a diagnostic test for clinical applications. Frontiers Media S.A. 2021-06-07 /pmc/articles/PMC8215886/ /pubmed/34164441 http://dx.doi.org/10.3389/fcvm.2021.671191 Text en Copyright © 2021 Li, Sun, Yang, Huang, Zhang, Wang, Guan, Yang, Wang, Meng, Zhou, Zhou, Luo, Hu, Jiang and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Li, Yahong Sun, Yun Yang, Lan Huang, Mingtao Zhang, Xiaojuan Wang, Xin Guan, Xianwei Yang, Peiying Wang, Yan Meng, Lulu Zhou, Ran Zhou, Xiaoyan Luo, Chunyu Hu, Ping Jiang, Tao Xu, Zhengfeng Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics |
title | Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics |
title_full | Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics |
title_fullStr | Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics |
title_full_unstemmed | Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics |
title_short | Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics |
title_sort | analysis of biomarkers for congenital heart disease based on maternal amniotic fluid metabolomics |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215886/ https://www.ncbi.nlm.nih.gov/pubmed/34164441 http://dx.doi.org/10.3389/fcvm.2021.671191 |
work_keys_str_mv | AT liyahong analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT sunyun analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT yanglan analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT huangmingtao analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT zhangxiaojuan analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT wangxin analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT guanxianwei analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT yangpeiying analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT wangyan analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT menglulu analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT zhouran analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT zhouxiaoyan analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT luochunyu analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT huping analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT jiangtao analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics AT xuzhengfeng analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics |